Sun Pharma

Project prepared and presented by:

Jinia BiswasSruti JainVibhav Kaushal

HISTORY

• 1983 – Sun Pharma established with five psychiatry products and two person marketing team at Vapi, Gujarat.

• 1994 – Sun Pharma went public in an issue that was oversubscribed 55 times.

• 1989 – Exports to neighbouring countries began.• 2000 – Sun Pharma ranked 5th largest pharmaceutical

company in India.• 2007 – Sun Pharma demerged into a separate entity Sun

Pharma Advanced Research Company, the first research company to get listed on stock exchanges in India.

• 2012 – Major acuisitions in US completed.

BOARD OF DIRECTORS

Chairman – Israel MakovManaging Director – Dilip S. ShanghviExecutive Director – Sudhir V. Valia, Sailesh

DesaiNon-executive independent director –

Hasmukh Shah, Keki M. Mistry, Ashwin Dani, S. Mohanchand Dadha.

AWARDS 2012

Business Leadership Of The Year -Pharmaceutical – NDTV Profit

Most outstanding Company Of The Year – CNBC TV 18 India Business Leader Award

Listed on World’s 100 Most Innovative Companies – Forbes

Listed on Asia’s Fab 50 - Forbes

ACUISITIONS & JOINT VENTURES

Generic Business of URL Pharma , United States

Dusa Pharmaceuticals Inc, United StatesJoint Venture with MSDAcquired Caraco Pharmaceutical Laboratories

LtdAcquired Taro Pharmaceutical Industries LtdAcquired Inwood Laboratories Incorprated

SHARE PRICE

As on 26th November, 2013 : BSE Rs 587.55, 7.00(+1.21%) , Volume 17,147

As on 26th November, 2013 : NSE Rs 587.70, 6.85(+1.18%), Volume

150,672

SUN PHARMA INDUSTRIES STOCK PRICE

P/E 652.30 P/C(Based on standalone numbers) 443.17

BOOK VALUE(Rs) 41.64 PRICE BOOK(Based on standalone numbers) 13.94

DIVIDEND(%) 250.00% DIVIDEND YIELD(%) 0.43%

MARKET LOT 1 FACE VALUE(Rs) 1

INDUTSRY P/E 32.03 DELIVERABLES(%) 69.85

CONTRIBUTION TO SENSEXCOMPANY NAME

INDUSTRY LAST PRICE

CHANGE Rs (%)

MARKET CAPITALIZATION (CRORES)

CONTRIBUTION

SUN PHARMA PHARMACEUTICAL 587.70 7.15 1.23 48688.92 8.56

CIPLA DO 390.75 3.45 0.89 20393.20 2.68

DR.REDDY’S LAB

DO 2438.00 -1.30 -0.05 31102.74 -0.24

CONTRIBUTION TO NIFTYCOMPANY LAST PRICE CHANGE

Rs (%)MARKET

CAP(CRORES)CONTRIBUTION

SUN PHARMA 589.80 8.95 1.54 122,157.25 2.07

LUPIN 853.50 2.90 0.34 38251.99 0.15

CIPLA 390.60 3.50 0.90 31362.11 0.31

RANBAXY 428.00 3.05 0.72 18110.47 0.14

DR.REDDY’S LAB

2446.80 6.65 0.27 41620 0.13

DIVIDEND HISTORYFinancial Year

Interim/Final

Rate of Dividend

Dividend per

equity share(Rs

Face Value

Book Closure

From To

Date of declaratiof dividend

2007-2008

Final 210% 10.50 Rs 5 27/08/08 6/09/08 6/09/08

2008-2009

Final 275% 13.75 Rs 5 25/08/09 5/09/09 11/09/09

2009-2010

Final 275% 13.75 Rs 5 14/09/10 24/09/10 24/09/10

2010-2011

Final 350% 3.50 Re 1 6/09/11 16/09/11 16/09/11

2011-2012

Interim 425% 4.25 Re 1 16/08/12 Record Date

10/18/12

TREND ANALYSIS

KEY PERFORMANCE INDICATORSINDICATOR/

YEARTOTAL INCOME PROFIT FOR

THE YEARRESERVE & SURPLUS

EARNINGS PER SHARE

NET BLOCK

2008-2009 44808 18780 69414 87.8 14625

2009-2010 42123 13470 77254 65.2 15328

2010-2011 60827 18161 93798 17.5 25214

2011-2012 84910 26567 121322 25.7 29295

2012-2013 116880 29831 148862 28.8 45145

21st ANNUAL REPORT FOR THE YEAR ENDED MARCH 31, 2013

Particulars Year ended March 31,2013(Rs in

million)

Year ended March 31, 2012(Rs in

million)Total Income 26,683 43,584

Profit After Tax 5,166 16,975

Dividend on Equity Shares 5,178 4,401

Corporate Dividend Tax 880 714

Transfer to various reserves 520 2,000

Amount of dividend per equity share of Re 1 each

2.50 4.25

Book Value per equity share of Re 1 each

75 76

EXPENDITURE ON R & D Year ended March 31, 2013(Rs in million)

Year ended March 31, 2012(Rs in million)

Capital 377.2 352.1

Revenue 2725 1831.9

Total 3102.2 2184

Total R&D as a % of Total Turnover

13.8% 9.1%

CURRENT NEWS ON SUN PHARMA• Sun Pharmaceutical Industries Ltd gained 1 per cent after unit Taro

Pharmaceutical Industries announced the start of a tender offer to buy back up to $200 million of its ordinary shares.

• Sun Pharma's stake in Taro will go up to more than 69 per cent from 66 per cent should the buyback be fully subscribed.

• MUMBAI: The impregnable walls around top defensive stocks such as ITC and Sun

Pharma have cracked, as they have lost nearly 10% from their October peaks against NSE Nfity's fall of just a little over 1%. These stocks are among the biggest losers in benchmark Nfity during the past month.

• Pharma leader Sun Pharma is trading at 40 times, which is the highest among its peers.

• Drug Controller General of India has ordered Sun Pharmaceutical, the country's largest drug maker by m-cap, to suspend clinical research activities at its Mumbai based bio-analytical laboratory, a move that could slow down its regulatory filings in India and overseas as well.

• The company has upped its revenue growth guidance to 25% for FY14 over the previously announced range of 18-20%, but analysts are sceptical of sustainability of margins.

http://www.unitedworld.edu.in/CampusAhmedabad Campus: Karnavati Knowledge Village, A/907,Uvarsad, S.G.Highway, Gandhinagar

Kolkata Campus: Infinity Benchmark Tower 10th Floor, Plot - G1, Block - EP& GP, Sec - V, Salt Lake, Kolkata.

Reg. Office: 407, Zodiac Square, 4th Floor Opp. Gurudwara, S.G. Road, Bodakdev, Ahmedabad.